AAP
NAUT icon

Arax Advisory Partners’s Nautilus Biotechnolgy NAUT Stock Holding History

Arax Advisory Partners’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-148
Closed -$125 – 4381
2025
Q3 		$125 Buy
+148
New +$109 ﹤0.01% 3483

Other funds holding NAUT

ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CM
Cercano Management Bellevue, Washington $750M AUM 25.77% 1-Year Est. Return
MVG
Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CFM
Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $4.42B AUM 22.6% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
ST
Sentinel Trust Houston, Texas $1.13B AUM 24.31% 1-Year Est. Return

Arax Advisory Partners's NAUT Position: Q4 2025 in Review

Arax Advisory Partners sold out of Nautilus Biotechnolgy (NAUT) in Q4 2025, closing a stake of 148 shares — an estimated $125 sold.

Arax Advisory Partners first reported a position in NAUT in Q3 2025 and held it in 1 quarter. The position peaked at $125 in Q3 2025. 68 funds tracked by Wall St. Rank hold NAUT as of Q4 2025.

  • Arax Advisory Partners reported no remaining Nautilus Biotechnolgy position as of Q4 2025 after selling out during the quarter.
  • Arax Advisory Partners sold 148 Nautilus Biotechnolgy shares in Q4 2025, an estimated $125.
  • Arax Advisory Partners first reported a position in Nautilus Biotechnolgy in Q3 2025 and held it in 1 quarter.
  • Arax Advisory Partners's Nautilus Biotechnolgy position peaked at $125 in Q3 2025.
  • 68 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q4 2025.

Based on Arax Advisory Partners's 13F filing for Q4 2025, filed 13 Feb 2026.